[go: up one dir, main page]

WO2007032818A3 - Composés et compositions permettant de contrôler une croissance cellulaire anormale - Google Patents

Composés et compositions permettant de contrôler une croissance cellulaire anormale Download PDF

Info

Publication number
WO2007032818A3
WO2007032818A3 PCT/US2006/027860 US2006027860W WO2007032818A3 WO 2007032818 A3 WO2007032818 A3 WO 2007032818A3 US 2006027860 W US2006027860 W US 2006027860W WO 2007032818 A3 WO2007032818 A3 WO 2007032818A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
ccdtht
class
body weight
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/027860
Other languages
English (en)
Other versions
WO2007032818A2 (fr
Inventor
Zoltan Kiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoltan Laboratories LLC
Original Assignee
Zoltan Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoltan Laboratories LLC filed Critical Zoltan Laboratories LLC
Priority to EP06787717A priority Critical patent/EP1931332A4/fr
Publication of WO2007032818A2 publication Critical patent/WO2007032818A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007032818A3 publication Critical patent/WO2007032818A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L’invention concerne une classe de composés, contenant traditionnellement un groupe trialkylammonium, ayant été synthétisés et caractérisés comme étant des composés anticancéreux. Un élément représentatif de cette classe, l’iodure de N,N-diéthyl-N-méthyl-2-[(9-oxo-9H-thioxanthèn-2-yl)méthoxy]éthanaminium (CCDTHT), s’est avéré réduire le volume tumoral dans divers modèles de tumeurs, améliorer les effets d’autres agents chimiothérapeutiques, dont le cisplatine, réduire la perte de poids corporel induite par la chimiothérapie et augmenter la survie d’animaux co-traités au moyen de quantités toxiques de cisplatine. Le CCDTHT présentait même de meilleurs effets sur le volume tumoral, le poids corporel et la survie lorsqu’il était administré à des animaux conjointement à la phosphatase alcaline placentaire humaine. Ces composés contenant un groupe trialkylammonium et des phosphatases alcalines, notamment lorsqu’ils sont combinés les uns avec les autres ou à d’autres traitement, peuvent être utilisés pour traiter un cancer ou d’autres maladies à prolifération cellulaire.
PCT/US2006/027860 2005-09-12 2006-07-19 Composés et compositions permettant de contrôler une croissance cellulaire anormale Ceased WO2007032818A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06787717A EP1931332A4 (fr) 2005-09-12 2006-07-19 Composés et compositions permettant de contrôler une croissance cellulaire anormale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71634605P 2005-09-12 2005-09-12
US60/716,346 2005-09-12

Publications (2)

Publication Number Publication Date
WO2007032818A2 WO2007032818A2 (fr) 2007-03-22
WO2007032818A3 true WO2007032818A3 (fr) 2009-04-02

Family

ID=37865419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027860 Ceased WO2007032818A2 (fr) 2005-09-12 2006-07-19 Composés et compositions permettant de contrôler une croissance cellulaire anormale

Country Status (3)

Country Link
US (3) US7589083B2 (fr)
EP (1) EP1931332A4 (fr)
WO (1) WO2007032818A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1973561T1 (sl) * 2005-12-15 2011-07-29 Chemgen Corp Encimi, ki zmanjĺ ujejo imunski stres
WO2007081654A2 (fr) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions et méthodes pour rehausser la viabilité et la fonction de cellules d'îlot
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
US7423029B1 (en) * 2007-03-23 2008-09-09 Zoltan Laboratories, Llc Compounds to promote regeneration of bone marrow
US20090030066A1 (en) * 2007-07-23 2009-01-29 Zoltan Laboratories Llc Small molecules for the protection of pancreatic cells
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (fr) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Formulations de phosphatase alcaline intestinale
US12318434B2 (en) 2019-05-06 2025-06-03 Theriva Biologics, Inc. Alkaline phosphate-based oncology treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512520A (en) * 1950-06-20 Hydroxyalkylaminoalkyl phenothi
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
DE844154C (de) * 1946-12-09 1952-07-17 Rhone Poulenc Sa Verfahren zur Herstellung von Phenthiazinderivaten mit einer externen quartaeren Ammoniumgruppe
US4183912A (en) * 1978-01-16 1980-01-15 American Home Products Corporation Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
GB8529448D0 (en) * 1985-11-29 1986-01-08 Ward Blenkinsop & Co Ltd Thioxanthone derivatives
WO1998049172A1 (fr) * 1997-04-28 1998-11-05 University Of Vermont Benzothiopyranopyridines regioisomeres a activite antitumorale
JP4636656B2 (ja) * 1999-07-08 2011-02-23 株式会社松風 歯科用接着剤組成物
US6410192B1 (en) * 1999-11-15 2002-06-25 Corning Incorporated Photolithography method, photolithography mask blanks, and method of making
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US20030212061A1 (en) * 2002-03-12 2003-11-13 Haydar Simon N. Aza-thioxanthenones with antitumor activity
US6767919B2 (en) * 2002-12-17 2004-07-27 Walker Cancer Research Institute, Inc. High specificity anticancer agents
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIN ET AL.: "Syntheses and Properties of Water Soluble Thioxanthone Photoinitiators.", YINGYONG HUAXUE, vol. 16, no. 5, 1999, pages 25 - 28, XP008111447 *
LIN ET AL.: "Synthesis of Water Soluble Photoinitiators ofThioxanthone Derivatives III.", HUADONG LIGONG DAXUE XUEBAO, vol. 26, no. 2, 2000, pages 212 - 214, 220, XP008111445 *
QIAN ET AL.: "Photochemistry Study on new Water Soluble Thioxanthone.", GUANGPUXUE YU GUANGPU FENXI, vol. 20, no. 6, 2000, pages 807 - 809, XP008111446 *
See also references of EP1931332A4 *

Also Published As

Publication number Publication date
EP1931332A2 (fr) 2008-06-18
WO2007032818A2 (fr) 2007-03-22
US7943606B2 (en) 2011-05-17
US7589083B2 (en) 2009-09-15
US20100048668A1 (en) 2010-02-25
US20070060634A1 (en) 2007-03-15
EP1931332A4 (fr) 2010-06-23
US20100022617A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2006007384A3 (fr) Antibiotiques contenant des complexes de l'acide borinique, et leur procede d'utilisation
WO2004056322A3 (fr) Antibiotiques contenant des complexes d'acide borinique et leurs procedes d'utilisation
WO2006113623A3 (fr) Elimination d'une population de cellules heterogenes ou mixtes dans des tumeurs
WO2007112403A3 (fr) Prévention et traitement des lésions d'ischémie-reperfusion et des états associés
WO2007147128A3 (fr) Médicament anti-cancéreux non toxique combinant de l'ascorbate, du magnésium et une naphtoquinone
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
BRPI0916356A2 (fr)
WO2007058776A3 (fr) Proteines de fusion a intron du facteur de croissance des hepatocytes
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007044693A3 (fr) Compositions liquides, ioniques, multifonctionnelles pour vaincre le polymorphisme et conferer de meilleures proprietes a des ingredients actifs pharmaceutiques, biologiques, nutritionnels et energetiques
WO2008091620A3 (fr) Polythérapie
WO2005005414A3 (fr) Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant
WO2007034321A3 (fr) Compositions pharmaceutiques a activite cicatrisante comprenant au moins un derive de dextrane soluble et au moins un facteur de croissance derive des plaquettes
WO2006096828A3 (fr) Proteines chimeriques possedant des domaines de liaison a phosphatidylserine
WO2007032818A3 (fr) Composés et compositions permettant de contrôler une croissance cellulaire anormale
WO2006124012A3 (fr) Composes pour le traitement de la maladie d'alzheimer et pour l'inhibition de la production du peptide amyloide beta
WO2007038868A3 (fr) Nouveau compose d'enediyne et ses utilisations
WO2007064968A3 (fr) Compositions pharmaceutiques stables de 5,10 methylenetetrahydrofolate
PT1765360E (pt) Utilizações antivirais de complexos de ácido borínico
UA95224C2 (ru) Антацидная фармацевтическая композиция в порошковой форме, фармацевтическое средство, ее содержащее, и способ ее получения
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO2003057012A8 (fr) Acide s-dimethyl-arsino-thiosuccinique, acide s-dimethyl-arsino-2-thiobenzoique, s-(dimethyl-arsino) glutathione utilises comme traitements anticancereux
WO2005058934A3 (fr) Derives steroides glycosyles a activite anti-migratoire
Sindhu et al. Carotenoid lutein protects the kidney against cisplatin-induced acute renal failure
WO2006096759A3 (fr) Methodes et compositions destinees a traiter le cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006787717

Country of ref document: EP